369 related articles for article (PubMed ID: 18560389)
1. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
Sessa C; Guibal A; Del Conte G; Rüegg C
Nat Clin Pract Oncol; 2008 Jul; 5(7):378-91. PubMed ID: 18560389
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic therapy: concept to clinic.
Young RJ; Reed MW
Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
[TBL] [Abstract][Full Text] [Related]
3. [Interests in angiogenesis inhibitor drugs approved for the treatment of cancers].
Bennis Y; Guillet B; Curti C; Pisano P
Therapie; 2010; 65(2):95-105. PubMed ID: 20478241
[TBL] [Abstract][Full Text] [Related]
4. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
Barrascout E; Medioni J; Scotte F; Ayllon J; Mejean A; Cuenod CA; Tartour E; Elaidi R; Oudard S
Bull Cancer; 2010; 97():29-43. PubMed ID: 20418202
[TBL] [Abstract][Full Text] [Related]
5. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Quesada AR; Medina MA; Alba E
Bioessays; 2007 Nov; 29(11):1159-68. PubMed ID: 17935210
[TBL] [Abstract][Full Text] [Related]
6. [Antiangionic drugs in soft tissue sarcoma].
Salas S; Huynh T; Deville JL; Duffaud F
Bull Cancer; 2010 Jun; 97(6):701-5. PubMed ID: 20483703
[TBL] [Abstract][Full Text] [Related]
7. Targeting angiogenesis in esophagogastric adenocarcinoma.
Okines AF; Reynolds AR; Cunningham D
Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
[TBL] [Abstract][Full Text] [Related]
8. How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
Brower V
J Natl Cancer Inst; 2009 Jun; 101(12):846-7. PubMed ID: 19509354
[No Abstract] [Full Text] [Related]
9. [Angiogenesis targeting in renal carcinomas].
Pouessel D; Culine S
Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
[TBL] [Abstract][Full Text] [Related]
10. [The role of angiogenesis in renal carcinoma].
Bussolati B; Satolli MA; Camussi G
G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
[TBL] [Abstract][Full Text] [Related]
11. Design of clinical trials of radiation combined with antiangiogenic therapy.
Senan S; Smit EF
Oncologist; 2007 Apr; 12(4):465-77. PubMed ID: 17470689
[TBL] [Abstract][Full Text] [Related]
12. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
English BC; Price DK; Figg WD
Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
[No Abstract] [Full Text] [Related]
13. Novel agents for the treatment of advanced kidney cancer.
Cooney MM; Remick SC; Vogelzang NJ
Clin Adv Hematol Oncol; 2004 Oct; 2(10):664-70. PubMed ID: 16163253
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy for breast cancer.
Nielsen DL; Andersson M; Andersen JL; Kamby C
Breast Cancer Res; 2010; 12(5):209. PubMed ID: 21067536
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with antiangiogenic therapy in leukemia.
Wellbrock J; Fiedler W
Curr Cancer Drug Targets; 2011 Nov; 11(9):1053-68. PubMed ID: 21999626
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis as a therapeutic target in urothelial carcinoma.
Pinto A; Redondo A; Zamora P; Castelo B; Espinosa E
Anticancer Drugs; 2010 Nov; 21(10):890-6. PubMed ID: 20729712
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies for kidney cancer in urologic practice.
Haas NB; Uzzo RG
Urol Oncol; 2007; 25(5):420-32. PubMed ID: 17826664
[TBL] [Abstract][Full Text] [Related]
18. [Anti-angiogenic drugs].
Sato Y
Nihon Rinsho; 2010 Jun; 68(6):1054-8. PubMed ID: 20535955
[TBL] [Abstract][Full Text] [Related]
19. [Effect of angiogenesis inhibitors on renal cell carcinoma].
Bodrogi I
Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis in cancer: molecular mechanisms, clinical impact.
Eichhorn ME; Kleespies A; Angele MK; Jauch KW; Bruns CJ
Langenbecks Arch Surg; 2007 May; 392(3):371-9. PubMed ID: 17458577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]